<?xml version='1.0' encoding='utf-8'?>
<document id="28093990"><sentence text="Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy." /><sentence text="Tyrosine kinase inhibitors (TKIs) are widely used drugs which have high availability in reducing the activity of BCR-ABL1 tyrosine kinase, therefore they play an indispensable role in the treatment of Chronic myeloid leukemia (CML)"><entity charOffset="0-8" id="DDI-PubMed.28093990.s2.e0" text="Tyrosine" /><entity charOffset="122-130" id="DDI-PubMed.28093990.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.28093990.s2.e0" e2="DDI-PubMed.28093990.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28093990.s2.e0" e2="DDI-PubMed.28093990.s2.e1" /></sentence><sentence text=" Imatinib, dasatinib and nilotinib have been proved to have absolute bioavailability and stable blood concentration in humans"><entity charOffset="1-9" id="DDI-PubMed.28093990.s3.e0" text="Imatinib" /><entity charOffset="11-20" id="DDI-PubMed.28093990.s3.e1" text="dasatinib" /><entity charOffset="25-34" id="DDI-PubMed.28093990.s3.e2" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.28093990.s3.e0" e2="DDI-PubMed.28093990.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28093990.s3.e0" e2="DDI-PubMed.28093990.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28093990.s3.e0" e2="DDI-PubMed.28093990.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28093990.s3.e1" e2="DDI-PubMed.28093990.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28093990.s3.e1" e2="DDI-PubMed.28093990.s3.e2" /></sentence><sentence text=" TKIs pharmacokinetics has close relationships with the clinical response and clinical treatment of CML" /><sentence text="" /><sentence text="We conducted a systematic PubMed search to look for studies relating to TKIs pharmacokinetics with proper inclusion/exclusion criteria" /><sentence text=" After looking through a large number of references, we investigated that different generations of TKIs could be influenced by many factors" /><sentence text=" We chose some typical factors which were closely linked to the common treatment of CML" /><sentence text=" These factors contain daily dose, diet, individual variability, drug-drug interaction, drugs resistance and drug withdrawal" /><sentence text="" /><sentence text="By summarizing up these influence factors, we hope it can make a contribution to clinical therapy" /><sentence text=" Above all, the relationship between influence factors and the clinical therapeutic effect is the key point that our research pays attention to" /><sentence text="" /><sentence text="This review highlights certain influence factors of TKIs clinical pharmacokinetics" /><sentence text="" /></document>